Natrol Q2 earnings
This article was originally published in The Tan Sheet
Executive Summary
Natrol reported net income of $100,000 on net sales of $16.6 mil. during the second-quarter (ended June 30) marking the company's "second consecutive quarter of profitability," Natrol President and CEO Wayne Bos said Aug. 14. The gains represented a turnaround from the first two quarters of 2005 when Natrol reported a net loss of $300,000 on net sales of $37.3 mil. "We have achieved profitability by being sharply-focused on the core business," Bos said...
You may also be interested in...
Natrol Sees More Deals In The Future; Looks To Tailor, Balance Portfolio
An exclusive manufacturing and distribution deal with H57 Nutrition for Original South African H57 Hoodia is a feather in Natrol's cap following several acquisitions and licensing deals in the past three weeks
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.